生产企业：Leal Therapeutics, Inc.
LTX-001 is a first-in-class brain-penetrant oral GLS1 inhibitor being developed by Leal Therapeutics for schizophrenia. The Phase 1b/2a trial (NCT07734493) in adults with schizophrenia has been initiated, with initial data expected by year-end.
LTX-001 is a first-in-class brain-penetrant oral GLS1 inhibitor being developed by Leal Therapeutics for schizophrenia. The Phase 1b/2a trial (NCT07734493) in adults with schizophrenia has been initiated, with initial data expected by year-end.
First-in-class brain-penetrant oral GLS1 (glutaminase 1) inhibitor
精神分裂症（schizophrenia）— 在研适应症，Phase 1b/2a 临床试验（NCT07734493）进行中
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
